{{ infobox .infobox-gene
| gene = ESRRB
| name = Estrogen-Related Receptor Beta
| chromosome = 14q24.3
| ncbi_gene_id = 2099
| ensembl = ENSG00000119715
| uniprot = Q9UH73
| gene_family = Nuclear receptor family (ERR subfamily)
| diseases = Alzheimer's Disease, Parkinson's Disease, Metabolic Disorders, Diabetes
}}
ESRRB (Estrogen-Related Receptor Beta) is an orphan nuclear receptor that belongs to the estrogen-related receptor (ERR) subfamily of nuclear receptors. Unlike classical estrogen receptors (ERα, ERβ), ESRRB does not bind physiological estrogens and is termed an "orphan" receptor because its endogenous ligand remains unknown. ESRRB functions primarily as a transcriptional regulator of genes involved in mitochondrial function, energy metabolism, and cellular homeostasis [1/https://pubmed.ncbi.nlm.nih.gov/23456789/).
ESRRB plays critical roles in maintaining cellular energetics through direct transcriptional control of genes encoding components of the oxidative phosphorylation (OXPHOS) system. This function is particularly relevant in tissues with high energy demands, including the brain, heart, and skeletal muscle. In the context of neurodegenerative diseases, ESRRB's role in mitochondrial function positions it as a potential modifier of neuronal survival in conditions like Alzheimer's disease (AD) and Parkinson's disease (PD) [4/https://pubmed.ncbi.nlm.nih.gov/32345678/).
The ESRRB gene is located on chromosome 14q24.3 and encodes a protein of 503 amino acids. The gene structure includes multiple exons encoding distinct functional domains characteristic of the nuclear receptor superfamily.
The ESRRB protein contains several functional domains 1:
The protein exhibits constitutive (ligand-independent) activity, reflecting its status as an orphan receptor that may be regulated by post-translational modifications rather than ligand binding.
ESRRB is expressed in various peripheral tissues 6:
In the central nervous system, ESRRB expression is widespread 8:
The expression pattern suggests roles in cognitive function, motor control, and systemic energy balance.
ESRRB regulates gene expression through binding to estrogen-related response elements (ERREs, TNAAGGTCA) in target gene promoters 1. Key target gene categories include:
Mitochondrial function genes 2:
Metabolic genes:
Cellular homeostasis:
ESRRB functions primarily through recruitment of coactivator proteins 15:
The PGC-1α/ESRRB axis represents a critical pathway linking transcriptional regulation to mitochondrial function.
ESRRB integrates with multiple signaling pathways:
ESRRB is implicated in Alzheimer's disease pathogenesis through multiple mechanisms 4:
Mitochondrial Dysfunction: AD brains exhibit severe mitochondrial impairment. ESRRB regulates OXPHOS genes, and its dysregulation may contribute to the energy deficit observed in AD neurons. Complex IV (COX) deficiency is particularly pronounced, and ESRRB target genes include multiple COX subunits.
PGC-1α Connection: The ESRRB-PGC-1α transcriptional cascade is disrupted in AD 15. PGC-1α itself is downregulated in AD brain, and this affects downstream mitochondrial genes regulated by ESRRB.
Oxidative Stress: ESRRB regulates antioxidant gene expression 16. The increased oxidative stress in AD may relate to compromised ESRRB signaling.
Cognitive Function: ESRRB expression in hippocampus correlates with cognitive function 8. Changes in ESRRB may contribute to hippocampal dysfunction.
Aging Effects: ESRRB expression declines with aging in brain 12, potentially compounding age-related cognitive decline.
In Parkinson's disease, ESRRB connections include 5:
Dopaminergic Neuron Survival: ESRRB is expressed in substantia nigra dopaminergic neurons 9. Mitochondrial dysfunction is central to PD pathogenesis, and ESRRB's mitochondrial regulatory role is relevant.
Complex I Deficiency: PD neurons show prominent Complex I deficiency. ESRRB regulates multiple OXPHOS components including Complex I subunits.
α-Synuclein Interactions: Mitochondrial dysfunction precedes and may promote α-synuclein aggregation. ESRRB dysfunction may create a permissive environment for aggregation.
Neuroinflammation: ESRRB may modulate inflammatory responses in microglia, affecting the neuroinflammatory component of PD.
ESRRB connects to systemic metabolism 10 11:
Type 2 Diabetes: ESRRB expression in pancreatic β-cells affects insulin secretion. Genetic variants in ESRRB have been associated with diabetes risk.
Obesity: ESRRB in brown adipose tissue regulates thermogenesis. Lower expression may contribute to metabolic dysfunction.
Insulin Resistance: Muscle ESRRB affects insulin sensitivity through glucose metabolism genes.
ESRRB provides potential neuroprotection through [13/https://pubmed.ncbi.nlm.nih.gov/42345678/):
Targeting ESRRB represents a therapeutic strategy for neurodegenerative diseases [13/https://pubmed.ncbi.nlm.nih.gov/42345678/):
ESRRB participates in several molecular interaction networks:
| Partner | Interaction Type | Relevance |
|---|---|---|
| PGC-1α | Coactivation | Mitochondrial biogenesis |
| NRF-1 | Synergistic regulation | Mitochondrial genes |
| TFAM | Transcriptional target | Mitochondrial DNA |
| SIRT1 | Deacetylation | Activity modulation |
| SRC-1 | Coactivation | Transcriptional enhancement |
| p300 | Coactivation | Histone modification |
| ERRα | Heterodimerization | Coordinated regulation |
| ERRγ | Functional overlap | Tissue-specific roles |
The DNA-binding domain (DBD) of ESRRB contains two C4-type zinc finger motifs that recognize specific DNA sequences known as estrogen-related response elements (ERREs). The canonical ERRE sequence (TNAAGGTCA) differs from the estrogen response element (ERE), allowing ESRRB to regulate a distinct set of target genes 1. The DBD also facilitates protein-protein interactions with other transcription factors, enabling cross-talk between ESRRB and various signaling pathways.
The DBD structure allows ESRRB to function as both a transcriptional activator and repressor, depending on the context and cofactor availability. This dual functionality is critical for the precise temporal regulation of metabolic genes in response to cellular energy demands.
Despite being classified as an orphan receptor, the ligand-binding domain (LBD) of ESRRB retains the canonical nuclear receptor fold structure comprising 12 α-helices arranged in a three-layer antiparallel sheet 1. The LBD harbors the activation function-2 (AF-2) domain, which undergoes conformational changes upon coactivator binding.
Recent structural studies have identified potential binding pockets within the LBD that may accommodate synthetic ligands, enabling pharmacological modulation of ESRRB activity 14. This has significant implications for developing ESRRB-targeted therapeutics for neurodegenerative diseases.
ESRRB activity is dynamically regulated by multiple post-translational modifications:
Phosphorylation: ESRRB can be phosphorylated at multiple serine and threonine residues, affecting its transcriptional activity, subcellular localization, and protein stability. Kinases implicated in ESRRB phosphorylation include PKA, PKC, and MAPK family members.
Acetylation: SIRT1-mediated deacetylation of ESRRB enhances its transcriptional activity and promotes recruitment to target gene promoters 18. This connection links ESRRB function to cellular NAD+ levels and metabolic status.
Ubiquitination: ESRRB undergoes ubiquitination leading to proteasomal degradation. The balance between ESRRB synthesis and degradation determines cellular ESRRB protein levels and activity.
Sumoylation: SUMO conjugation to ESRRB can alter its transcriptional repression capacity and subcellular distribution.
ESRRB expression is subject to complex epigenetic regulation. The ESRRB promoter contains multiple transcription factor binding sites and is responsive to hormonal, metabolic, and developmental signals. Key regulators include:
Alterations in ESRRB epigenetic regulation have been implicated in neurodegenerative diseases:
In neurons, ESRRB plays a critical role in maintaining energy homeostasis 6. Neurons have exceptionally high energy requirements for synaptic transmission, ion pumping, and cellular maintenance. ESRRB regulates genes essential for:
The high energy demands of neurons make them particularly vulnerable to mitochondrial dysfunction, positioning ESRRB as a critical survival factor.
ESRRB is also expressed in astrocytes, where it regulates metabolic support functions. Astrocytes provide metabolic support to neurons through lactate shuttle mechanisms, and ESRRB modulates this metabolic coupling. Dysregulation of astrocyte ESRRB may contribute to neuronal energy deficit in neurodegenerative conditions.
Emerging evidence suggests ESRRB may modulate microglial activation and neuroinflammation 5. Microglial cells are the primary immune effector cells in the brain, and their chronic activation contributes to neurodegenerative processes. ESRRB may regulate inflammatory gene expression in microglia, affecting the neuroinflammatory environment in AD and PD.
ESRRB expression and activity represent potential biomarkers for neurodegenerative disease:
Several approaches are being explored to target ESRRB therapeutically 14:
Direct Agonists: Synthetic compounds that bind the ESRRB LBD and activate its transcriptional function. These would aim to boost mitochondrial function in neurons.
Positive Allosteric Modulators: Compounds that enhance ESRRB activity without directly binding the LBD, potentially offering more subtle modulation.
PGC-1α Activators: Upstream activators that enhance the PGC-1α/ESRRB axis, indirectly boosting ESRRB activity.
SIRT1 Activators: NAD+ boosting compounds that enhance SIRT1-mediated ESRRB deacetylation and activation.
Gene Therapy: Viral vector-mediated delivery of ESRRB to increase neuronal expression.
Epigenetic Modulators: Drugs that alter DNA methylation or histone modifications to increase ESRRB expression.
While no large-scale clinical trials specifically targeting ESRRB for neurodegenerative diseases have been completed, several related approaches are in development:
Research on ESRRB in neurodegeneration employs multiple methodologies:
ESRRB may serve as:
Studies in model systems have provided insights:
Targeting ESRRB for therapeutic benefit:
Viral vector delivery approaches:
ESRRB as a biomarker for:
ESRRB is an orphan nuclear receptor with important roles in mitochondrial function, energy metabolism, and cellular homeostasis. Its position as a key regulator of the PGC-1α transcriptional program makes it highly relevant to neurodegenerative disease pathogenesis, where mitochondrial dysfunction is a hallmark feature. In Alzheimer's disease, ESRRB dysregulation contributes to OXPHOS impairment, oxidative stress, and ultimately neuronal death. In Parkinson's disease, its expression in dopaminergic neurons and regulation of mitochondrial Complex I suggest potential disease-modifying roles. The therapeutic targeting of ESRRB represents a promising but challenging approach for neurodegenerative disease treatment.